Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources. Here, we describe a high-throughput protocol for cloning, expressing, purifying, and evaluating bispecific antibodies. This protocol enables the rapid screenin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Danqing, Partin, Alexander C., Zhao, Liangjun, Chen, Irwin, Michaels, Mark L., Wang, Zhulun, Garces, Fernando, Gong, Danyang, Riley, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157557/
https://www.ncbi.nlm.nih.gov/pubmed/35664258
http://dx.doi.org/10.1016/j.xpro.2022.101428
_version_ 1784718659391848448
author Li, Danqing
Partin, Alexander C.
Zhao, Liangjun
Chen, Irwin
Michaels, Mark L.
Wang, Zhulun
Garces, Fernando
Gong, Danyang
Riley, Timothy P.
author_facet Li, Danqing
Partin, Alexander C.
Zhao, Liangjun
Chen, Irwin
Michaels, Mark L.
Wang, Zhulun
Garces, Fernando
Gong, Danyang
Riley, Timothy P.
author_sort Li, Danqing
collection PubMed
description Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources. Here, we describe a high-throughput protocol for cloning, expressing, purifying, and evaluating bispecific antibodies. This protocol enables the rapid screening of large panels of bispecific molecules to identify top candidates for further development. For complete details on the use and execution of this protocol, please refer to Estes et al. (2021).
format Online
Article
Text
id pubmed-9157557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91575572022-06-02 Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies Li, Danqing Partin, Alexander C. Zhao, Liangjun Chen, Irwin Michaels, Mark L. Wang, Zhulun Garces, Fernando Gong, Danyang Riley, Timothy P. STAR Protoc Protocol Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources. Here, we describe a high-throughput protocol for cloning, expressing, purifying, and evaluating bispecific antibodies. This protocol enables the rapid screening of large panels of bispecific molecules to identify top candidates for further development. For complete details on the use and execution of this protocol, please refer to Estes et al. (2021). Elsevier 2022-05-27 /pmc/articles/PMC9157557/ /pubmed/35664258 http://dx.doi.org/10.1016/j.xpro.2022.101428 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Li, Danqing
Partin, Alexander C.
Zhao, Liangjun
Chen, Irwin
Michaels, Mark L.
Wang, Zhulun
Garces, Fernando
Gong, Danyang
Riley, Timothy P.
Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title_full Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title_fullStr Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title_full_unstemmed Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title_short Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
title_sort protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157557/
https://www.ncbi.nlm.nih.gov/pubmed/35664258
http://dx.doi.org/10.1016/j.xpro.2022.101428
work_keys_str_mv AT lidanqing protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT partinalexanderc protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT zhaoliangjun protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT chenirwin protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT michaelsmarkl protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT wangzhulun protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT garcesfernando protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT gongdanyang protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies
AT rileytimothyp protocolforhighthroughputcloningexpressionpurificationandevaluationofbispecificantibodies

Ejemplares similares